MetaCap

MeiraGTx (MGTX) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Solid Biosciences (SLDB) has outperformed MeiraGTx (MGTX) over the past year, gaining 33.0% versus a gain of 7.0%. Over five years, MGTX leads with a -55.5% price change compared with -77.8% for SLDB. MeiraGTx is the larger company by market cap ($779.9 million vs $697.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MGTX+6.97%SLDB+32.98%
+144%+65%-13%
Nov 21, 20251 yearNov 20, 2026
MGTX-57.21%SLDB-79.06%
+33%-33%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MGTX versus SLDB key metrics
MetricMGTXSLDB
Share price$7.98$6.25
Market cap$779.89M$697.57M
1-day change-1.97%-2.95%
YTD return+0.38%+10.82%
1-year return+6.97%+32.98%
5-year return-55.54%-77.78%
P/E ratio (TTM)9.17—
EPS (TTM)$0.87$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$81.39M—
Revenue growth (YoY)+144.57%—
Net income (latest FY)$-114.20M$-174.32M
Operating margin-130.20%—
Net margin-140.31%—
52-week high$15.35$11.45
52-week low$6.62$4.65
Distance from 52-week high-48.01%-45.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+247.74%+199.36%
Average volume837.25K1.30M
Shares outstanding97.73M111.61M
Employees386121
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLDB has outperformed MGTX by 26.0 percentage points over the past year.

About MeiraGTx

MGTX stock →

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

MGTX vs SLDB FAQ

Which is bigger, MeiraGTx or Solid Biosciences?

MeiraGTx (MGTX) is larger, with a market capitalization of $779.89M compared with $697.57M for Solid Biosciences (SLDB).

Which stock has performed better over the past year, MGTX or SLDB?

SLDB returned +32.98% over the past 12 months, compared with +6.97% for MGTX (price return, excluding dividends). Past performance does not predict future results.

Are MeiraGTx and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons